GGrantIndex
Sort

40,608 grants matching prostate cancer

Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity

$363,250
Michael H Elliott · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2024 · EY

miR-205 Nanoparticle system circumvents docetaxel resistance in prostate cancer

$363,250
Murali Mohan Yallapu · University Of Texas Rio Grande Valley · SC1 · FY2022 · GM

Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity

$363,250
Michael H Elliott · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2025 · EY

P63 IN EPITHELIAL CELL PROLIFERATION AND DIFFERENTIATION

$363,219
Harvard University (Medical School) · R01 · FY2001 · CA

Design of Programmable Genotoxins

$363,201
John M Essigmann · Massachusetts Institute Of Technology · R01 · FY2007 · CA

Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer

$363,164
Min Sup Song · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer

$363,164
Min Sup Song · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Functional Interaction of Amyloid-b Protein with Glial Toll-Like Receptors

$363,127
Michael R. Nichols · University Of Missouri-St. Louis · R15 · FY2011 · AG

CD8+ T Cell-Mediated Immunotherapy of Autochthonous SV40 T Antigen-Induced Tumors

$363,051
Todd D Schell · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2014 · CA

Role of U19/Eaf2 in androgen-dependent prostate homeostasis

$363,009
Zhou Wang · University Of Pittsburgh At Pittsburgh · R37 · FY2013 · DK

Identification of Specific Antagonists that Bind Hedgehog and Block its Activity

$362,905
Kevin Peter Williams · North Carolina Central University · R15 · FY2011 · CA

Pharmacogenetic Studies

$362,893
Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA

Project 3: Extending Clinical Benefit by Selective Treatment of Resistant Lesions in mCRPC

$362,884
Robert Jeraj · University Of Wisconsin-Madison · P50 · FY2025 · CA

New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets

$362,803
James A Wells · University Of California, San Francisco · R01 · FY2020 · CA

Consequences and mechanism of aberrant splicing in African American prostate cancer disparities

$362,798
Norman H Lee · George Washington University · R01 · FY2018 · CA

Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors

$362,764
Joseph P Balthasar · State University Of New York At Buffalo · R01 · FY2020 · CA

Novel Herbal Medicine for the Treatment of Prostate Cancer

$362,763
Chendil Damodaran · University Of Kentucky · R01 · FY2007 · AT

Project 2: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment during tumor growth and progression in ATL

$362,735
Katherine Nelson Weilbaecher · Ohio State University · P01 · FY2021 · CA

Project 3: Induction of synthetic lethality with combined DNMT and PARP inhibition

$362,734
Srinivasan Yegnasubramanian · Johns Hopkins University · P50 · FY2024 · CA

Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors

$362,722
Joseph P Balthasar · State University Of New York At Buffalo · R01 · FY2021 · CA

Parp Function in Prostate Cancer

$362,689
Bryce M Paschal · University Of Virginia · R01 · FY2019 · CA

Chemoprevention of Colon Cancer, HDAC Inhibition, and Histone Status

$362,676
Roderick H Dashwood · Oregon State University · P01 · FY2012 · CA

Pooling of Prospective Studies of Diet and Cancer

$362,642
Stephanie A Smith-Warner · Harvard School Of Public Health · P01 · FY2008 · CA

Training Program in Cancer Biology

$362,640
Mary Elaine Reyland · University Of Colorado Denver · T32 · FY2019 · CA

Structure and Inhibition of the Conjugative DNA Relaxase-Helicase

$362,638
Matthew Redinbo · Univ Of North Carolina Chapel Hill · R01 · FY2009 · AI